We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

DCO:NYSEDucommun Incorporated Analysis

Data as of 2026-06-14 - not real-time

$164.54

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Ducommun (DCO) is trading at $164.54, comfortably above its 20‑day (150.0) and 50‑day (144.1) SMAs and the 200‑day SMA (114.1), confirming a bullish technical backdrop. However, the RSI of 68 signals an overbought condition and the price sits near the 52‑week high of $167.88, suggesting limited upside in the near term. The MACD histogram remains positive, reinforcing short‑term momentum but also warning of a potential pull‑back at resistance.
On the fundamentals side, the company posted a record $209 M Q1 revenue, up ~8% YoY, driven by a 17.5% surge in commercial aerospace and a 22% rise in missile business. Margins have improved, with adjusted EBITDA reaching 16% of revenue, yet the firm still reports a net loss (trailing EPS -$1.73) and a negative operating cash flow of $‑22.9 M. Debt stands at $342 M against $42 M of cash (D/E 51%), and the DCF‑derived fair value of $53.5 implies a ~32% downside from current pricing. The market sentiment is in “Extreme Greed” (Fear‑Greed Index 89.9), while volatility is elevated at 46% and beta exceeds 1.3, underscoring heightened risk.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Price near 52‑week resistance and RSI indicating overbought
  • Technical bullishness may fade without earnings beat
  • High valuation gap vs DCF fair value

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Sustained revenue growth in aerospace and defense segments
  • Improving operating margins and positive free cash flow
  • Elevated debt load and ongoing earnings turnaround risk

Long Term

> 3 years
Positive
Model confidence: 5/10

Key Factors

  • Long‑term secular demand for aerospace and defense products
  • Potential earnings recovery reflected in forward EPS of $5.08
  • Strategic initiatives highlighted at upcoming Investor Day

Key Metrics & Analysis

Financial Health

Revenue Growth8.60%
Profit Margin-3.43%
P/E Ratio32.4
ROE-4.23%
ROA4.55%
Debt/Equity51.16
P/B Ratio3.7
Op. Cash Flow$-22937000
Free Cash Flow$58.1M
Industry P/E30.6

Technical Analysis

TrendBullish
RSI68.3
Support$138.46
Resistance$167.88
MA 20$150.01
MA 50$144.15
MA 200$114.06
MACDBullish
VolumeStable
Fear & Greed Index89.86

Valuation

Fair Value$53.47
Target Price$164.00
Upside/Downside-0.33%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta1.34
Volatility46.04%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.